跳至主要内容
临床试验/NCT00518622
NCT00518622已完成1 期

A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients

Merck Sharp & Dohme LLC0 个研究点目标入组 40 人开始时间: 2007年7月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
40
主要终点
Safety and Tolerability of MK7009

研究概览

简要总结

The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is a man or a woman aged 18 to 55 years of age.
  • Subject has chronic Hepatitis C
  • Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period

排除标准

  • Patient has evidence of advanced liver disease.
  • Patient has human immunodeficiency virus (HIV)
  • Patient has Hepatitis B

结局指标

主要结局

Safety and Tolerability of MK7009

时间窗: 14 days after completion of study therapy

Number of participants who reported adverse experiences while on study medication as well as for 14 days after completion of study medication

Antiviral Activity of MK7009

时间窗: Baseline and Day 8

Change from Baseline in Log10 IU/mL hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 8

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验